Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Subcutaneous Cladribine for Nonrelapsing, Secondary Progressive Multiple Sclerosis (CLASP-MS): a Randomized, Placebo-controlled, Double-blind, Phase 2 Study.

NCT05961644 is registered in ClinicalTrials.gov with Institute of Psychiatry and Neurology, Warsaw as lead sponsor.

NCT NCT05961644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05961644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Subcutaneous Cladribine for Nonrelapsing, Secondary Progressive Multiple Sclerosis (CLASP-MS): a Randomized, Placebo-controlled, Double-blind, Phase 2 Study.
Lead sponsor
Institute of Psychiatry and Neurology, Warsaw
Phase
Phase 2/3
Overall status
Recruiting
Start date
October 3, 2022
Completion date
October 30, 2027
Enrollment
188 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, multiple sclerosis, secondary progressive